Neurocrine Biosciences

Neurocrine Biosciences discovers, develops and commercialises medicines for neurological, psychiatric, endocrine and immunological disorders. Founded in 1992 by scientists from the Salk Institute and Stanford University, the San Diego-based company has a portfolio of FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, classic congenital adrenal hyperplasia, hyperphagia in Prader-Willi syndrome, endometriosis and uterine fibroids.

The company describes a workforce of more than 2,000 people and a pipeline that includes multiple compounds in mid-to-late-stage clinical development. Its work spans laboratory discovery, clinical research and the commercialisation of medicines for underserved conditions, with some treatments developed in collaboration with other pharmaceutical companies.